Schrödinger, Inc. (NASDAQ:SDGR) Stock Holdings Increased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA raised its holdings in shares of Schrödinger, Inc. (NASDAQ:SDGR) by 53.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,228,123 shares of the company’s stock after acquiring an additional 427,594 shares during the period. Massachusetts Financial Services Co. MA owned approximately 1.69% of Schrödinger worth $23,752,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Texas Permanent School Fund Corp raised its stake in Schrödinger by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 47,869 shares of the company’s stock valued at $1,292,000 after acquiring an additional 626 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Schrödinger by 2.6% in the 2nd quarter. Louisiana State Employees Retirement System now owns 27,800 shares of the company’s stock worth $538,000 after buying an additional 700 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Schrödinger by 49.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock worth $41,000 after buying an additional 703 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Schrödinger by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 10,987 shares of the company’s stock worth $297,000 after buying an additional 753 shares in the last quarter. Finally, Illinois Municipal Retirement Fund raised its stake in shares of Schrödinger by 2.7% in the 1st quarter. Illinois Municipal Retirement Fund now owns 32,043 shares of the company’s stock worth $865,000 after buying an additional 831 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Schrödinger Stock Down 4.8 %

Shares of NASDAQ SDGR opened at $19.85 on Friday. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -10.56 and a beta of 1.51. The stock’s fifty day simple moving average is $20.79 and its 200 day simple moving average is $22.51. Schrödinger, Inc. has a 52-week low of $18.02 and a 52-week high of $38.00.

Schrödinger (NASDAQ:SDGR) last issued its quarterly earnings results on Wednesday, July 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.11. Schrödinger had a negative return on equity of 38.38% and a negative net margin of 100.42%. The business had revenue of $47.33 million for the quarter, compared to the consensus estimate of $40.19 million. As a group, analysts anticipate that Schrödinger, Inc. will post -2.19 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Morgan Stanley dropped their price objective on Schrödinger from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 21st. Leerink Partners assumed coverage on Schrödinger in a research note on Tuesday, July 2nd. They issued an “outperform” rating and a $29.00 price objective on the stock. Leerink Partnrs raised Schrödinger to a “strong-buy” rating in a research note on Tuesday, July 2nd. Finally, KeyCorp dropped their price objective on Schrödinger from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Schrödinger has a consensus rating of “Moderate Buy” and an average target price of $33.44.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.